Skip to main content

Published locations for Final phase 2 results testify to the clinical advantage of TACE plus sorafenib in unresectable HCC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Final phase 2 results testify to the clinical advantage of TACE plus sorafenib in unresectable HCC

User login

  • Reset your password
  • /content/final-phase-2-results-testify-clinical-advantage-tace-plus-sorafenib-unresectable-hcc
  • /fedprac/article/252970/hepatocellular-carcinoma/final-phase-2-results-testify-clinical-advantage